CN204745334U - Memory alloy silica gel is slow release system in utero - Google Patents
Memory alloy silica gel is slow release system in utero Download PDFInfo
- Publication number
- CN204745334U CN204745334U CN201520547848.6U CN201520547848U CN204745334U CN 204745334 U CN204745334 U CN 204745334U CN 201520547848 U CN201520547848 U CN 201520547848U CN 204745334 U CN204745334 U CN 204745334U
- Authority
- CN
- China
- Prior art keywords
- silica gel
- utero
- skeleton
- slow
- utility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The utility model discloses a memory alloy silica gel is slow release system in utero, the testing tool comprises a skeleto, the skeleton adopts the winding of super elastic memory wire to form adjacent two be equipped with the clearance between the super elastic memory wire, the parcel is equipped with the silica gel pipe wall that the mixture that adopts silica gel and nanometer copper was made on the skeleton, save to have in the skeleton and to pass the clearance with the left norethindrone particle in the pipe wall aperture of silica gel pipe wall. The utility model discloses a memory alloy silica gel is slow release system in utero mainly used prevention and treatment uterus gland myopathy, pelvis endometriosis, treatment menorrhalgia, proliferative phase endometrium, endometrium breed disease, prevention endometrium polyp and the recurring of chocolate cyst postoperative, women's contraception.
Description
Technical field
This utility model belongs to contraceptive and gyniatrics technical field, is specifically related to a kind of memorial alloy silica gel in utero slow-released system.
Background technology
Adenomyosis (adenomyosis) refers to that endometrial gland and interstitial are present in myometrium, and with compensatory hypertrophy and the hypertrophy of surrounding muscle layer cell, sickness rate reaches the 10%-47% of women population.Main clinical manifestation is menorrhagia, menostaxis and the dysmenorrhea of aggravating gradually, infertile etc.Its sickness rate increases year by year, has become common gynecological disease, frequently-occurring disease, and have a strong impact on patient's physical and mental health and quality of life, thus extremely industry is paid close attention to.
From the angle of pathology, Ectopic Endometrium in myometrium more is diffuse growth, involves rear wall in the majority, and Fructus Psoraleae palace is that uniformity increases, and increases obviously with anteroposterior diameter, spherical in shape.Because gland myopathy patient often exists the symptoms such as menorrhagia, dysmenorrhea be obvious (see 1.NabeshimaH, MurakamiT, NishimotoM, etal.Successfultotallaparoscopiccysticadenomyomectomyaft erunsuccessfulopensurgeryusingtranstrocarultrasonographi cguiding.JMinimInvasiveGynecol, 2008,15 (2): 227 – 30.2.ParazziniF,VercelliniP,PanazzaS,etal.Theriskfactorsforadenomyosis.HumReprod1997,12:1275–9。3.VavilisD, AgorastosT, TzafetasJ, etal.Adenomyosisathysterectomy:itsprevalenceanditsrelati onshiptotheoperativefindingsandthereproductiveandthemens trualfactors.ClinExpObstetGynaecol, 1997,24:36-38.), patient generally can actively seek treatment.
The clinical treatment of gland myopathy receives much attention always, and clinical treatment totally can be divided into two classes, and a class is the pregnancies with conservative treatment of Reservations uterus, comprises Drug therapy, naturopathy and conservative surgeries in treating (lesion resection); Two classes are treatment and the hysterectomy of non-Reservations uterus.
The medicine for the treatment of gland myopathy is various, as mifepristone, danazol, gestrinone, GnRH-a etc., have that Different therapeutical effect is large, side effect obviously, costly and the problem such as to recur after drug withdrawal (see 4.YangJ-H, HoH-N, YangY-S.Currentdiagnosticandtreatmentstrategiesforadenom yosis.ExpertRev.Obstet.Gynecol, 2006,1 (1): 111-120.).Naturopathy mainly contains high intensity focused ultrasound (HighIntensityFocusedUltrasound, HIFU), but there is apparatus expensive, to be non-ly generally suitable for, not thoroughly, easily the problem such as recurrence is (see 5.DongX in treatment, YangZ.High-intensityfocusedultrasoundablationofuterinelo calizedadenomyosis.CurrOpinObstetGynecol, 2010,22:326-330.6.MinZhou,Jin-YunChen,Liang-DanTang,Wen-ZhiChen,Zhi-BiaoWang.Ultrasound-guidedhigh-intensityfocusedultrasoundablationforadenomyosis:theclinicalexperienceofasinglecenter.FertilityandSterility,2011.95(3):900-905.）。Conservative operation dealing mainly contains uterine artery interventional embolization (Uterinearteryembolization, UAE), hysteroscope TCRE (transcervicalresectionofendometrium, and uterine lesion excision (resectionofuterinelesion, RUL) TCRE).These pregnancies with conservative treatment modes all exist that indication scope is little, not thoroughly, easily the problem such as recurrence is (see 7.Gupta in treatment, J.K, Sinha, A., Lumsden, etal.Uterinearteryembolizationforsymptomaticuterinefibro ids.CochraneDatabaseofSystematicReviews.2006,25 (1): CD005073.8.VashishtA,StuddJW,CareyAH."FibroidEmbolisation:ATechniqueNotWithoutSignificantComplications".BritishJournalofObstetrics&Gynecology.2000,107(9):1166–1170。9.WangCJ,YenCF,LeeCL,etal.Laparoscopicuterinearteryligationfortreatmentofsymptomaticadenomyosis.JAmAssocGynecolLaparosc2002,9(3):293-296。10. Xia Enlan, Duan Hua, Liu Yuhuan, Deng. the clinical practice of Transcervical Resection of Endometrium and late result analysis, China's journal of obstetrics and gynecology, 2004,39 (5): 296-300), thus make most of Patients with Adenomyosis, be that serious symptom and expectant treatment loser are finally forced to hysterectomize especially.
Uterus is the symbol of women and the important organ pipe of quality of life, and hysterectomy can cause many adverse effects to the physiology of women, psychology.Patients with Adenomyosis mostly is women at fertile age, in order to effective disease therapy, prevention of recurrence also retains patient uterine, applicant is through studying for a long period of time, propose according to Uterine lesion degree calibration, and select " Man Yuele (Mirena) three scheme " of therapeutic scheme to treat adenomyosis by calibration, and in wound " Shore Achates art (MUFU) " treatment, severe patient and additive method loser, achieve significant therapeutic effect (see 10. Xiao Yan ice, Zhao Jing, Li Qinghan, Deng. " flesh wall large portion excision-uterus Reconstruction " treatment in, severe adenomyosis---art formula and Research on safety. Zunyi Medical College's journal, 2012, 35 (4): 302-305.11. Zhao Jing, Li Qinghan, Fang Derong, etc. flesh wall large portion excision-uterus Reconstruction is combined in the happy treatment of the graceful moon, the curative effect [J] of severe adenomyosis. Chinese Human-Female children health care, 2013,15:2464-2466.12. side's morals are held, Zhao Jing, Li Qinghan, etc. the preliminary study [J] of happy treatment of graceful moon adenomyosis focus threshold value screening. Zunyi Medical College's journal, 2014,37 (4): 418-421).At present, applicant team has begun to take shape a whole set of system about the thought of adenomyosis calibration treatment, method, standard, scheme, operation and apparatus/drug research and development." happy three schemes of the graceful moon " and " Shore Achates art " based on calibration thought can avoid patient to hysterectomize because of gland myopathy from methodology.
The graceful moon, pleasure was a kind of New-type long-acting contraceptive device, was in recent years progressively applied to the correlational study in non-contraception field.Being happy to nineteen ninety the graceful moon goes on the market at European registration, and in 2000 in Discussion on Chinese Listed, in the same year, is gone on the market in the U.S. by FDA approval.The graceful moon, happy contained effective constituent was LNG (LNG, 52mg/ prop up), and LNG is the potent progestogen of synthetic, is the optically active body of racemization norgestrel, and activity is about 100 times of norethindrone.Levonorgestrel mainly acts on hypothalamus and hypophysis, and make the peak of midcycle FSH and LH level obviously reduce or disappear, ovary is not ovulated, and has obvious antiestrogenic, and cervical mucus retrogradation can be made to hinder Sperm penetration.Extremely strong progestin is shown to endometrial transformation, endometrium can be made thinning, and intimal epithelium cell is low cylindricality, and secretory function is bad, be unfavorable for implantation of ovum, thus have fabulous contraceptive effect (see: 13.http: //baike.baidu.com/view/569093.htm).
After the graceful moon, pleasure inserted cavity of uterus, the LNG left in vertical tube can quantitatively discharge (20 μm/d).Research shows, have the effect of prevention gynecopathy progress and recurrence after Man Yuele in utero places, and has certain therapeutical effect (see 14.Bednarek, P.H. to part gland myopathy (focus smaller), Jensen, J.T.Safety, efficacyandpatientacceptabilityofthecontraceptiveandnon-contraceptiveusesoftheLNG-IUS.Internationaljournalofwome n'shealth, 2010, 9 (1): 45 – 58.), its mechanism may be a kind of efficient progestogen at LNG contained in the inner, this hormone can keep high concentration and continuous action by film in uterus, fundamentally to change endometrial pathological state (see 15.WanYL, HollandC.Theefficacyoflevonorgestrelintrauterinesystemsf orendometrialprotection:asystematicreview.Climacteric.20 11, 14 (6): 622-32.), even if be there is dystopy by improved inner membrance in these, also can not cause the generation of gynecopathy (see: 16. bright scapes and. the Railway Project of the basic and clinic studies of endometriosis. Chinese practical gynecological and obstetrics' magazine, 2002, 18 (3): 129-130.16. bright scapes and. the basic and clinic studies [M] of endometriosis. Beijing: publishing house of China Concord Medical Science University, 2003,244-245.).These pharmacological properties of LNG, make Man Yuele have contraception concurrently, the effect of the diseases such as treatment gland myopathy, irregular menstruation.
But, find in the process of clinical practice, the following problems of happy existence of the graceful moon:
(1) the graceful moon, happy shape was "T"-shaped, therefore ring easily moves down, even obscission is obvious, and because its active ingredient (LNG) is stored in longitudinal tubule (L tubule), therefore, once ring moves down, its therapeutic effect will be affected or not have effect;
(2) support that the graceful moon is happy is organic plastics, when the LNG release in longitudinal tubule (L tubule) is complete or after a large amount of decay, because plastics are inert material, its contraceptive effect is by bright decline;
(3) the LNG dosage stored in longitudinal tubule (L tubule) is less than normal (52mg), is used for the treatment of object effect not ideal;
(4) expensive (1200 yuan ~ 1400 yuan /), once ring moves down, comes off or poor effect, can bring larger financial burden to patient.
Summary of the invention
In view of this, the purpose of this utility model is to provide a kind of memorial alloy silica gel in utero slow-released system, and it has prevention, treatment adenomyosis and some other gynaecopathia, has the effect of contraceptive effect simultaneously.
For achieving the above object, this utility model provides following technical scheme:
A kind of memorial alloy silica gel in utero slow-released system, comprise skeleton, described skeleton adopts super elastic memory metal silk to be entwined, and is provided with gap between adjacent two described super elastic memory metal silks, and on described skeleton, parcel is provided with the silica gel tube wall adopting the mixture of silica gel and Nanometer Copper to make; The LNG microgranule that can pass the tube wall aperture of described gap and described silica gel tube wall is stored in described skeleton.
Further, described skeleton adopts titanium-nickel memory alloy wires to be entwined.
Further, rounded, the palace shape of described skeleton or be inverted Ω shape.
The beneficial effects of the utility model are:
Memorial alloy silica gel of the present utility model in utero slow-released system, according to physicochemical property, the pharmacological property of LNG, the nanotechnology feature of silica gel, in conjunction with modern intrauterine device (IUD) production technology, provide one and there is prevention, treatment adenomyosis and some other gynaecopathia, there is the IUD of contraceptive effect simultaneously; Memorial alloy silica gel of the present utility model in utero slow-released system has following advantage:
1. adopt super elastic memory metal silk to be wound around and make skeleton, make IUD deformable, the placement of favourable IUD and taking-up;
2. skeleton is all silica gel tube wall parcel, can avoid the generation of bare mental stents IUD incarceration phenomenon;
The copper 3. with contraceptive efficacy exists with nano-form, naked copper IUD can be avoided to there is the burst release phenomenon (releasing product based on the oxide of copper, the oxidation product of the excessive release of this copper ion and a large amount of copper of generation may cause putting metrorrhagia, pain etc. after device) of copper ion at the placement initial stage;
4. being stored in LNG in skeleton can with microgranule individualism, or mixes with other materials and store, can by controlling the size in silica gel tube cinclides footpath, realize the quantitative release (slow release or control slow) of LNG;
5. the profile of memorial alloy silica gel of the present utility model in utero slow-released system is not " circular, palace shape or be inverted Ω shape ", primarily of skeleton and silica gel composition, can keep intrinsic shape and some tension in uterine cavity, yielding and come off;
6. can adjust LNG dosage in silica gel tube easily, by this system respectively or combine for contraception or therapeutic purposes.
Memorial alloy silica gel of the present utility model in utero slow-released system can be used for:
1. Prevention and Curation adenomyosis, endometriosis of pelvis;
2. menorrhagia, proliferative phase of endometrium, endometrial hyperplasia is treated;
3. endometrial polyp and chocolate cyst postoperative recurrence is prevented;
4. female contraception.
Accompanying drawing explanation
In order to make the purpose of this utility model, technical scheme and beneficial effect clearly, this utility model provides following accompanying drawing to be described:
Fig. 1 is the cross section structure schematic diagram of this utility model memorial alloy silica gel in utero slow-released system;
Fig. 2 is the structural representation of rounded super elastic memory metal silk skeleton;
Fig. 3 is the structural representation of the super elastic memory metal silk skeleton in palace shape;
Fig. 4 is the structural representation in the super elastic memory metal silk skeleton being inverted Ω shape.
Detailed description of the invention
Below in conjunction with the drawings and specific embodiments, the utility model is described in further detail, and to make those skilled in the art better can understand this utility model being implemented, but illustrated embodiment is not as to restriction of the present utility model.
As shown in Figure 1, be the cross section structure schematic diagram of this utility model memorial alloy silica gel in utero slow-released system.The memorial alloy silica gel in utero slow-released system of the present embodiment, comprise skeleton 1, described skeleton 1 adopts super elastic memory metal silk 2 to be entwined, be provided with gap 3 between adjacent two described super elastic memory metal silks 2, on described skeleton 1, parcel is provided with the silica gel tube wall 4 adopting the mixture of silica gel and Nanometer Copper to make.The LNG microgranule 5 that can pass the tube wall aperture of described gap 3 and described silica gel tube wall 4 is stored in described skeleton 1.
Further, described skeleton 1 adopts titanium-nickel memory alloy wires to be entwined, and skeleton 1 can be set to rounded, palace shape or be inverted Ω shape, and respectively as shown in figs 2-4, the super elastic memory metal silk skeleton 1 of the present embodiment is set to palace shape.
The memorial alloy silica gel in utero slow-released system of the present embodiment, according to physicochemical property, the pharmacological property of LNG, the nanotechnology feature of silica gel, in conjunction with modern intrauterine device (IUD) production technology, provide one and there is prevention, treatment adenomyosis and some other gynaecopathia, there is the IUD of contraceptive effect simultaneously; Memorial alloy silica gel of the present utility model in utero slow-released system has following advantage:
1. adopt super elastic memory metal silk to be wound around and make skeleton, make IUD deformable, the placement of favourable IUD and taking-up;
2. skeleton is all silica gel tube wall parcel, can avoid the generation of bare mental stents IUD incarceration phenomenon;
The copper 3. with contraceptive efficacy exists with nano-form, naked copper IUD can be avoided to there is the burst release phenomenon (releasing product based on the oxide of copper, the oxidation product of the excessive release of this copper ion and a large amount of copper of generation may cause putting metrorrhagia, pain etc. after device) of copper ion at the placement initial stage;
4. being stored in LNG in skeleton can with microgranule individualism, or mixes with other materials and store, can by controlling the size in silica gel tube cinclides footpath, realize the quantitative release (slow release or control slow) of LNG;
5. the profile of memorial alloy silica gel of the present utility model in utero slow-released system is not " circular, palace shape or be inverted Ω shape ", primarily of skeleton and silica gel composition, can keep intrinsic shape and some tension in uterine cavity, yielding and come off;
6. can adjust LNG dosage in silica gel tube easily, by this system respectively or combine for contraception or therapeutic purposes.
The memorial alloy silica gel of the present embodiment in utero slow-released system can be used for:
1. Prevention and Curation adenomyosis, endometriosis of pelvis;
2. menorrhagia, proliferative phase of endometrium, endometrial hyperplasia is treated;
3. endometrial polyp and chocolate cyst postoperative recurrence is prevented;
4. female contraception.
The above embodiment is only for absolutely proving the preferred embodiment that this utility model is lifted, and protection domain of the present utility model is not limited thereto.The equivalent alternative or conversion that those skilled in the art do on this utility model basis, all within protection domain of the present utility model.Protection domain of the present utility model is as the criterion with claims.
Claims (3)
1. a memorial alloy silica gel in utero slow-released system, it is characterized in that: comprise skeleton, described skeleton adopts super elastic memory metal silk to be entwined, be provided with gap between adjacent two described super elastic memory metal silks, on described skeleton, parcel is provided with the silica gel tube wall adopting the mixture of silica gel and Nanometer Copper to make; The LNG microgranule that can pass the tube wall aperture of described gap and described silica gel tube wall is stored in described skeleton.
2. memorial alloy silica gel according to claim 1 in utero slow-released system, is characterized in that: described skeleton adopts titanium-nickel memory alloy wires to be entwined.
3. memorial alloy silica gel according to claim 1 in utero slow-released system, is characterized in that: described skeleton is rounded, palace shape or be inverted Ω shape.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520547848.6U CN204745334U (en) | 2015-07-27 | 2015-07-27 | Memory alloy silica gel is slow release system in utero |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520547848.6U CN204745334U (en) | 2015-07-27 | 2015-07-27 | Memory alloy silica gel is slow release system in utero |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN204745334U true CN204745334U (en) | 2015-11-11 |
Family
ID=54460096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201520547848.6U Expired - Fee Related CN204745334U (en) | 2015-07-27 | 2015-07-27 | Memory alloy silica gel is slow release system in utero |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN204745334U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104998344A (en) * | 2015-07-27 | 2015-10-28 | 肖雁冰 | Memory alloy silicone rubber intrauterine sustained-release system |
-
2015
- 2015-07-27 CN CN201520547848.6U patent/CN204745334U/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104998344A (en) * | 2015-07-27 | 2015-10-28 | 肖雁冰 | Memory alloy silicone rubber intrauterine sustained-release system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wildemeersch et al. | Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system | |
| Costa et al. | Management of ambiguous genitalia in pseudohermaphrodites: new perspectives on vaginal dilation | |
| Youm et al. | Factors affecting the spontaneous expulsion of the levonorgestrel-releasing intrauterine system | |
| US20110271963A1 (en) | Novel intra uterine device | |
| Wu et al. | Performance of the frameless GyneFix and the TCu380A IUDs in a 3-year multicenter, randomized, comparative trial in parous women | |
| Prabhakaran et al. | In-office retrieval of intrauterine contraceptive devices with missing strings | |
| Mansour | Modern management of abnormal uterine bleeding–the levonorgestrel intra-uterine system | |
| Bartlewski et al. | Assessing the usefulness of prostaglandin E2 (Cervidil) for transcervical artificial insemination in ewes | |
| CN204745334U (en) | Memory alloy silica gel is slow release system in utero | |
| Cirstoiu et al. | Levonorgestrel-releasing intrauterine systems: Device design, biomaterials, mechanism of action and surgical technique | |
| Hao et al. | Neovaginal prolapse treated with sacrospinous ligament suspension: a case report and review of the literature | |
| Trivedi et al. | Hysteroscopic management of intra-uterine devices with lost strings | |
| CN104998344A (en) | Memory alloy silicone rubber intrauterine sustained-release system | |
| McLafferty et al. | Male and female reproductive systems and associated conditions | |
| Ingle et al. | A Brief review on intra-uterine drug delivery systems | |
| US20150335413A1 (en) | Medical instruments kit and method for treating uterus prolapse | |
| US11642502B2 (en) | Device positionable in the uterine cavity and method of treatment thereof | |
| CN220554555U (en) | Non-bracket fixed levonorethindrone intrauterine drug delivery device | |
| CN204050646U (en) | The intrauterine medicine slow-release device for the treatment of adenomyosis | |
| CN102988401B (en) | Application of adenosine triphosphate or medicinal salt of adenosine triphosphatein in preparation of medicine for treating endometriosis | |
| Rao | Menorrhagia | |
| Woodman et al. | Menstrual disturbances | |
| Wong et al. | Adenomyosis and HIFU Ablation | |
| Chia et al. | 406 Neonate with mixed gonadal dysgenesis: challenges in sex assignment | |
| Melnychuk et al. | TREATMENT OF ENDOMETRIOSIS-ASSOCIATED PAIN ACCORDING TO THE RECOMMENDATIONS OF THE ESHRE ENDOMETRIOSIS GUIDELINE 2022 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151111 Termination date: 20160727 |